Company Overview and News

 
Sector Shakeup: Telecom Sector To Be Broadened And Renamed Communications Services

18h seekingalpha
Many investors typically counted on the Telecommunications sector as a defensive one that offered higher yields. That line of thinking is likely to no longer apply.

 
PayPal Holdings Inc Is a Better Bet on Financial Services

18h investorplace
Given its persona as the once-exclusive payment processor for mother ship eBay Inc (NASDAQ:EBAY) and recent parent of peer-to-peer payment app Venmo (extremely popular with millennials and Gen Zers), it seems more like a debt-fueled young tech firm launched out on its own from its mother ship.

 
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

18h seekingalpha
Glenview Capital Management’s 13F portfolio value decreased from $18.50B to $17.10B this quarter. The number of positions decreased from 58 to 52.

 
Adobe Systems To Acquire Magento Commerce For Integrated Ecommerce

2018-05-23 seekingalpha
The deal is likely one of more to come for Adobe as it uses its balance sheet and recent stock price appreciation to expand its offerings.

1
Why did eBay Inc.'s Senior Vice President Sell Over $1.3 Million Worth of Stock in Company?

2018-05-23 accesswire
BOCA RATON, FL / ACCESSWIRE / May 23, 2018 / On Friday, the discloser of eBay Inc.'s (NASDAQ: EBAY) Senior Vice President, Marie Huber's sale transaction has some investors wondering why.

 
Walmart's India (Flipkart) Gambit: Growth Rebirth Or Costly Facelift?

2018-05-23 seekingalpha
Walmart announced that it would pay $16 billion to acquire a 77% stake in Flipkart, an Indian online retail firm.

1
Criteo: Healthy Growth Company In A Fierce Environment

2018-05-22 seekingalpha
Financials are good for Criteo with stable margins, a rising bottom line, and very little debt.

1
Tracking Carl Icahn's Portfolio - Q1 2018 Update

2018-05-21 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.

 
EBAY / eBay, Inc. null

2018-05-18 sec.gov
Shareholder Alert Please vote against 4

 
CLPS IPO: It Is Undervalued, But I Am Not A Buyer

2018-05-18 seekingalpha
I don’t appreciate that the parent company is located in Cayman Islands. The fact that the business is Chinese does not help either.

1
Amazon Brings Its Cross-Border Ambitions to Alibaba's Backyard - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
3 Tech Stocks That Are Way Better Buys Than eBay Inc

2018-05-16 investorplace
Is eBay Inc (NASDAQ:EBAY) a terrible stock to own? Not necessarily. It has decent growth and a reasonable valuation. But it’s missing a certain “it” factor that other tech companies have right now.

 
EBAY / eBay, Inc. null

2018-05-16 sec.gov
Shareholder Alert Please vote against 4 Ratification o

2
EBAY / eBay, Inc. 8-K (Current Report)

2018-05-15 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
EBAY / eBay, Inc. DEFA14A

2018-05-15 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 278642103